As of 2025-06-10, the Intrinsic Value of Boston Scientific Corp (BSX) is 71.34 USD. This BSX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 100.04 USD, the upside of Boston Scientific Corp is -28.70%.
The range of the Intrinsic Value is 42.45 - 197.60 USD
Based on its market price of 100.04 USD and our intrinsic valuation, Boston Scientific Corp (BSX) is overvalued by 28.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 42.45 - 197.60 | 71.34 | -28.7% |
| DCF (Growth 10y) | 57.05 - 243.53 | 91.93 | -8.1% |
| DCF (EBITDA 5y) | 42.00 - 70.91 | 53.53 | -46.5% |
| DCF (EBITDA 10y) | 56.45 - 94.75 | 71.64 | -28.4% |
| Fair Value | 34.35 - 34.35 | 34.35 | -65.66% |
| P/E | 42.19 - 65.76 | 52.22 | -47.8% |
| EV/EBITDA | 34.76 - 59.55 | 50.41 | -49.6% |
| EPV | 21.73 - 29.16 | 25.45 | -74.6% |
| DDM - Stable | 19.66 - 100.06 | 59.86 | -40.2% |
| DDM - Multi | 37.04 - 146.22 | 59.07 | -41.0% |
| Market Cap (mil) | 148,004.17 |
| Beta | 0.83 |
| Outstanding shares (mil) | 1,479.45 |
| Enterprise Value (mil) | 158,588.17 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.06% |
| Cost of Debt | 4.25% |
| WACC | 6.83% |